Phase 3 trial was stopped on a positive interim analysis by DSMB and in consultation with FDA
Interim analysis was performed on approximately half of the total enrolled patients (775 of the 1550).
Trial included many delta and other variant patients
—————
Efficacy
• ~50% reduction in hospitalization (14.1% PBO vs 7.3% drug)
• 100% reduction in deaths (8 PBO vs 0 drug)
—————Safety
• fewer adverse reactions in the drug arm vs PBO (40% PBO vs 35% drug)
—————[Merck Ridgeback press release] https://www.businesswire.com/news/home/20211001005189/en/Mer...
[clinicaltrials.gov] https://clinicaltrials.gov/ct2/show/NCT04575597?term=molnupi...